BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SciLifeLab - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SciLifeLab
X-ORIGINAL-URL:https://www.scilifelab.se
X-WR-CALDESC:Events for SciLifeLab
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211028T130000
DTEND;TZID=Europe/Stockholm:20211028T140000
DTSTAMP:20260403T194600
CREATED:20210930T150158Z
LAST-MODIFIED:20211014T151926Z
UID:58266-1635426000-1635429600@www.scilifelab.se
SUMMARY:[Drug Discovery Seminars] Targeting the oncogenic TGFβ signaling pathway in cancer to inhibit invasion and metastasis
DESCRIPTION:Maréne Landström \n\n\n\nOctober 28\, 13:00-14:00 \n\n\n\n \n\n\n\nregistration\n\n\n\nWelcome to join this Drug Discovery Seminar hosted by the Drug Discovery and Development Platform. \n\n\n\nPresenter: \n\n\n\nProfessor Maréne Landström\, M.D.\, PhD \n\n\n\nDept. Medical Biosciences\, Umeå University \n\n\n\nMaréne Landström is a professor in Pathology at Department of Medical Biosciences\, Umeå University\, Sweden. She has made her postdoctoral training at the Ludwig Institute of Cancer Research\, Uppsala Branch and have also been a group leader at Department of Immunology\, Genetics and Pathology\, Uppsala University before taking on her current position. \n\n\n\nAbstract: \n\n\n\nTransforming growth factor beta (TGFb) is frequently overexpressed in several forms of cancer including prostate cancer and this has been shown to correlate with poor prognosis. TGFb is transducing its canonical and non-canonical signals via its transmembrane TGFb Type II and Type I receptors (TbRII/TbRI) which are serine-threonine kinases. We have found that the TbRI undergoes proteolytic cleavage in cancer cells in a manner dependent on the ubiquitin-ligase tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6). The intracellular domain of TbRI (TbRI-ICD) is released from the cell membrane\, soluble and is transported to the nucleus in some specific forms of cancer to promote expression of genes causing invasion and metastatic growth. In collaboration with SciLifeLab DDD we have generated potential therapeutic antibodies to target this pathway which we are investigating the function of\, in our established preclinical models for prostate cancer.
URL:https://www.scilifelab.se/event/drug-discovery-seminars-targeting-the-oncogenic-tgf%ce%b2-signaling-pathway-in-cancer-to-inhibit-invasion-and-metastasis/
LOCATION:Online event via Zoom
CATEGORIES:Event
END:VEVENT
END:VCALENDAR